Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...

Executive Spotlights

Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

1 min read

Edwards Lifesciences Acquires Innovalve Bio Medical Ltd. for $300M

Irvine, CA, July 15, 2024 (Business Wire) -- Edwards Lifesciences has acquired Innovalve Bio Medical Ltd. for $300 million to enhance its TMVR technologies. The acquisition follows Innovalve’s promising clinical progress since 2017. Innovalve will now operate within Edwards' TMTT product group, addressing unmet needs in structural heart treatments.

Read full article here.

Comments

Life Science Headlines

Terray Therapeutics Secures $120M in Series B Funding to Revolutionize Small Molecule Drug Development with Advanced AI

ViaNautis Bio Appoints Dr. Adi Hoess as CEO to Propel Growth in Genetic Therapies

AvenCell Therapeutics Secures $112M in Series B Funding to Advance Innovative Switchable CAR-T Cell Therapies

Mike Alvarez Appointed CEO of Glooko to Drive Growth Following $100 Million Series F Financing

Seaport Therapeutics Secures $225M in Oversubscribed Series B Financing to Propel Neuropsychiatric Drug Development

ShiraTronics Series B Raises $66M

Keith Dionne, Ph.D. Appointed CEO of Luxa Biotechnology

CeriBell upsizes IPO, targets $578M valuation

Halda Therapeutics appoints Christian Schade as President and CEO to advance novel cancer therapies

Kailera Therapeutics raises $400M to advance next-generation obesity therapies